Photo: Science Business

No Communication Regarding Permission For 2-Dose Regimen Of ZyCoV-D: Zydus Life

Zydus Life has clarified that there has been no official communication regarding permission for the two-dose regimen of the needle-less ZyCoV-D vaccine. ZyCov-D, an indigenous DNA-plasmid-based vaccine against Sars-Cov-2, was given emergency use authorisation for restricted use last year by the Central Drugs Standard Control Organisation (CDSCO). The three-dose vaccine was found to be over 66% effective in the third phase clinical trial.

Tue, 19 Apr 2022 - 06:55 PM / by Varun Das

Tags: Covid-19, Coronavirus Vaccines, vaccines campaigns, Zydus Cadila, Needleless Vaccine

Courtesy: Live Mint

Zydus Cadila's ZyCoV-D vaccine

Photo: WION

Govt Likely To Extend Expiry Date For Zydus Cadila's COVID-19 Vaccine

The Central Government is likely to extend expiry date of Zydus Cadila's ZyCoV-D vaccine against COVID-19 for children. Set to launch in January 2021, the expiration is expected to be extended by three more months and will be given to children aged between 15 to 17 years. Besides Zydus Cadila's vaccine, Bharat Biotech's COVAXIN will also be given to the children's vaccination drive, set to begin from January 3.

Mon, 27 Dec 2021 - 04:29 PM / by Varsha Joshi

Tags: Zydus Cadila, zycov-D, Children Vaccination, Union government, Expiry Date

Zydus Cadillac vaccine.

Photo: Economic Times

Indian Govt Places Order For 1 Crore Zydus Cadila COVID-19 Vaccine 

The order of 1 crore Zydus Cadila’s three-dose Covid vaccines has been placed by the Indian government at 265 rupees per dose. Reportedly, the world's first DNA-based vaccine is given at day zero, day 28th and then on the 56th day. The vaccine will be administered with a needle-free applicator, called ''PharmaJet''. ''The pricing has been decided in consultation with the Government of India," said the Gujarat-based firm.

Mon, 08 Nov 2021 - 07:03 PM / by SAM RAHUL RAJASHEKHAR

Tags: covid 19, Coronavirus, Coronavirus Vaccines, Zydus Cadila, India

Courtesy: Mint

ZyCoV-D Covid Vaccine

Photo: The Tribune

Zydus Cadila: Only Needle-Free COVID Vaccine Gets Emergency Use Approval

Vaccine maker Zydus Cadila's needle-free three-dose Covid-19 vaccine finally got approval for emergency use in India by the Indian drug regulator's subject committee expert. The Ahmedabad-based company had applied for the approval of its vaccine ZyCoV-D, on July 1. Reportedly, the vaccine can be given to adults and children above 12 years of age for the first time in India. Zydus is planning on making over 100 million doses yearly.

Sat, 21 Aug 2021 - 10:58 AM / by Prateek Chakradhar

Tags: Zydus Cadila, Covid Vaccination, DGCI, Indian drug manufacturer

Courtesy: NDTV

Zydus Cadila Vaccine

Photo: The Print

Ahmedabad-Based Zydus Cadila's Covid Vaccine Awaits Govt Approval

After conducting the largest clinical trials in more than 50 centers, Zydus Cadila's three-dose Covid vaccine "ZyCoV-D" may soon get the government's approval for emergency use in India. The Gujarat-based pharmaceutical company has been listed for emergency use authorization (EAU) with the Indian Drug regulator and is likely to produce around 10-12 crore doses in a year. Reportedly, the ZyCoV-D vaccination will be administered to the adults… read-more

Mon, 09 Aug 2021 - 06:35 PM / by Prateek Chakradhar

Tags: Zydus Cadila, Covid-19, Covid Vaccination, Emergency Use Authorization

Courtesy: ANI

Zydus HQ

Photo: The Financial Express

Zydus COVID-19 Vaccine For Children To Launch Shortly In India

The government on June 27 declared that the vaccination process for children aged between 12 to 18 may start by July-end or August as the trials for Zydus Cadila is almost complete. The Zydus Cadila vaccine Zy-CoV-D will soon apply for authorisation for emergency use to the Drugs Controller General of India. The vaccine is asserted to be safe for use in both children and adults.

Mon, 28 Jun 2021 - 06:55 PM / by Sohini Mandal

Tags: Zydus Cadila, Coronavirus Vaccines, DRUG CONTROLLER GENERAL OF INDIA, Emergency Use Authorization

Courtesy: The Times of India

Zydus Cadila

Photo: The News Minute

COVID Drug 'Virafin' By Zydus To Cost Rs 11,995 Per Dose

Pharmaceutical giant Zydus Cadila has announced that a dose of its COVID-19 drug 'Virafin' will cost Rs 11,995. The company has claimed that Virafin will lessen the need for oxygen in COVID-19 patients. The drug was earlier approved by the Drug Controller General of India on April 23 for treatment of mild COVID-19 cases.  Meanwhile, Zydus is also in the process to launch its three-dose COVID-19 vaccine Zy-CoV-D.

Wed, 12 May 2021 - 12:39 PM / by Nikita Thakur

Tags: Zydus Cadila, Virafin, Covid-19, Covid Vaccine

Courtesy: India Today

Zydus Cadila

Photo: Business Standard

Zydus Cadila Tests COVID-19 Drug, Seeks DCGI's Regulatory Approval

Ahmedabad-based Zydus Cadila has sought approval from the drug regulator to use its viral hepatitis drugs to treat COVID-19. Zydus has claimed that during the phase-3 trial, its drugs - Pegyalated Interferon Alpha 2b and PegiHepTM - resulted in 91.15% efficacy. The drugs also reduced the supplemental oxygen need of patients from 84 to 56 hours. Moreover, the hepatitis B and hepatitis C-treating drug ‘PegIFN’ is a single-dose affordable… read-more

Mon, 05 Apr 2021 - 08:36 PM / by Nikita Thakur

Tags: Coronavirus, Drug Controller, Zydus Cadila, Covid-19

Courtesy: Hindustan Times